Table 3.

Currently ongoing clinical trials on MIP for conditions other than leprosy

Study	Primary objective	Number of participants
ICMR TB Consortium study et al.[46]	To compare the percentage of confirmed TB cases among healthy household contacts of newly diagnosed sputum-positive pulmonary TB patients in the vaccinated and placebo groups from two months after the first dose of vaccine till 38-month follow-up period.	12000
Patel et al.[47]	Number of participants (healthy subjects with recent history of close contact with COVID-19 patients) acquiring COVID-19 till eight weeks after the first dose	4000
Sudan et al.[48]	To compare the COVID-19 symptoms relief over the time, to compare the difference in proportion of patients with improved clinical outcome, and to compare the duration for conversion of COVID-19-positive status to negative in patients receiving MIP vs placebo	50
Prabhash et al.[49]	To compare safety, assess tumor response rate, compare PFS, and compare EORTC QOL	834

TB=Tuberculosis, PFS=Progression-free survival, EORTC QOL=European Organization for Research and Treatment of Cancer Quality of Life